Core Viewpoint - The announcement details the resignation of senior management personnel XINHUI HU from Kailaiying Pharmaceutical Group due to personal reasons, with no impact on the company's operations [1][2]. Group 1 - XINHUI HU submitted a written resignation report to the board of directors, effective upon delivery [1]. - As of the announcement date, XINHUI HU did not hold any shares in the company, indicating that his departure will not affect the company's normal business operations [1]. - The company and its board expressed gratitude for XINHUI HU's contributions during his tenure, highlighting his diligence and commitment to business development [1].

Core Viewpoint - The company announced the resignation of senior management personnel Xinhui Hu due to personal reasons, effective immediately upon submission of the resignation report to the board [1] Group 1 - Xinhui Hu submitted a written resignation report to the company's board [1] - The resignation is in accordance with the Company Law and the company's articles of association [1] - The resignation takes effect from the date it was delivered to the board [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Asymchem Laboratories (Tianjin) Co., Ltd. 凱萊英醫藥集團（天津）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6821） 海外監管公告 本海外監管公告乃由本公司根據香港聯合交易所有限公司證券上市規則第 13.10B 條作 出。 茲載列本公司在深圳證券交易所網站刊登的以下資料中文全文，僅供參閱。 承董事會命 於本公告日期，本公司董事會由董事長兼執行董事 Hao Hong 博士，執行董事楊蕊女 士、張達先生及洪亮先生，非執行董事 Ye Song 博士及張婷女士，以及獨立非執行董 事孫雪嬌博士、侯欣一博士及謝維愷先生組成。 证券代码：002821 证券简称：凯莱英 公告编号：2025-058 凯莱英医药集团（天津）股份有限公司 关于高级管理人员离任的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大 ...

Group 1 - The company Kailaiying announced the resignation of senior executive Xinhui Hu due to personal reasons, effective immediately upon submission of the resignation report to the board [1] - For the first half of 2025, the company's revenue composition shows that the pharmaceutical industry accounts for 99.9% of total revenue, while other businesses contribute only 0.1% [1] - The current market capitalization of Kailaiying is 39.9 billion yuan [2]

凯莱英医药集团（天津）股份有限公司 关于高级管理人员离任的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 凯莱英医药集团（天津）股份有限公司（以下简称"公司"）董事会近日收 到公司高级管理人员XINHUI HU先生递交的书面离任报告。XINHUI HU先生因个人 原因，申请辞去公司高管职务。根据《公司法》和《公司章程》等有关规定，XINHUI HU先生的书面离任报告自送达董事会之日生效。 截至本公告披露日，XINHUI HU先生未直接持有公司股份，其离任不会影响 公司生产经营活动的正常开展。XINHUI HU先生任职期间，勤勉尽责，恪尽职守， 积极推动公司业务发展。公司及公司董事会对XINHUI HU先生在任期间对公司发 展所作出的贡献表示衷心的感谢！ 特此公告。 凯莱英医药集团（天津）股份有限公司董事会 证券代码：002821 证券简称：凯莱英 公告编号：2025-058 二〇二五年九月二日 ...

截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 凱萊英醫藥集團（天津）股份有限公司 呈交日期: 2025年9月1日 I. 法定/註冊股本變動 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06821 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 27,553,260 | RMB | | | 1 RMB | | 27,553,260 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 27,553,260 | RMB | | | 1 RMB | | 27,553,260 | | 2. 股份分類 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 凱萊英醫藥集團（天津）股份有限公司 呈交日期: 2025年9月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06821 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 27,553,260 | RMB | | | 1 RMB | | 27,553,260 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 27,553,260 | RMB | | | 1 RMB | | 27,553,260 | 第 2 頁 共 11 ...

Group 1 - CRO concept stocks have shown significant gains, with WuXi AppTec (603259) up 6.3% at HKD 114.7, WuXi Biologics (02269) up 6.02% at HKD 35.2, and others like Kanglong Chemical (300759) and Kelaiying (002821) also experiencing notable increases [1] - Dongwu Securities reports that 22 CXO listed companies are expected to see revenue, net profit attributable to shareholders, and net profit excluding non-recurring gains and losses grow by 14.16%, 64.03%, and 24.82% year-on-year for the first half of 2025, respectively [1] - The second quarter of 2025 is projected to show further improvement in revenue and profit growth rates, with expected increases of 15.15% in revenue and 53.58% in net profit attributable to shareholders [1] Group 2 - Xiangcai Securities highlights the active performance of the innovative drug industry chain under the backdrop of national encouragement for innovation, despite ongoing pressures from medical insurance cost control [2] - The establishment of a multi-tiered payment system and the rigid demand for medical services are expected to stabilize and rebound the industry [2] - Companies in the pharmaceutical outsourcing services sector, particularly in ADC CDMO and peptide CDMO for weight loss drugs, are recommended for attention, including WuXi AppTec, Haoyuan Pharmaceutical, and WuXi Biologics [2]

Investment Rating - The report provides a positive outlook on the MASH non-invasive diagnosis technology, suggesting it could accelerate new drug development in the pharmaceutical and biotechnology sector [2]. Core Insights - The pharmaceutical and biotechnology sector experienced a decline of 0.65% from August 25 to August 29, underperforming compared to the Wind All A index (1.9%) and the CSI 300 index (2.71%). Only the medical research outsourcing (4.9%) and other biological products (0.14%) sectors saw gains, while in vitro diagnostics (-4.12%), raw materials (-3.34%), and vaccines (-0.59%) faced significant declines [2][7]. - The FDA has accepted the proposal for using VCTE-LSM as a reasonable alternative endpoint for clinical trials in adults with MASH and moderate to advanced fibrosis. This non-invasive method is expected to enhance patient compliance and could lead to a surge in drug development in the MASH area within the next two to three years [2][13]. - The report emphasizes the potential for domestic companies in China to leverage their cost advantages and forward-looking strategies in the field of non-invasive companion diagnostics, particularly in the MASH drug development competition [2]. Market Weekly Review - The pharmaceutical and biotechnology sector's performance was notably weaker than the broader market indices, with specific sub-sectors like medical research outsourcing and other biological products showing resilience [7][8]. - Individual stocks such as Tianchen Medical (30.1%), Ailis (25.6%), and Maiwei Biotech-U (22.4%) performed well, while stocks like Lifang Pharmaceutical (-13.9%), Yuekang Pharmaceutical (-11.9%), and Kanghua Biotech (-11.1%) faced significant losses [10][12]. Industry News and Key Company Announcements - On August 28, Kangfang Biotech announced that its drug AK112 received approval for treating advanced non-squamous non-small cell lung cancer, with promising clinical trial results expected to be presented at an international conference [12]. - The report highlights various companies' financial performances, with notable revenue changes and profit margins, indicating a mixed outlook across the sector [16][17].

| 表格序號 | 大股東/董事/最高行政人員名 作出披露的 買入 / 費出或涉及的 每股的平均價 | | | | 持有權益的股份數目 佔已發行的 有關事件的日期相關 | | --- | --- | --- | --- | --- | --- | | | 博 | 原因 | 股份數目 | | (請參閱上述 * 註 有投票權股 (日 / 月 / 年) 權 | | | | | | | 解) 份百分比 | | | | | | | ( 96 ) | | CS20250827E00351 | Norges Bank 1101(L) HKD 92.0514 | | | 235,600(L) | 4,053,000(L) 14.71(L)26/08/2025 | 追加内容 本文作者可以追加内容哦 ! 增持后，Norges Bank最新持股数目为405.3万股，持股比例由13.85%上升至14.71%。 | 股份代號: | 06821 | | --- | --- | | 上市法國名稱: | 凱萊英醫藥集團(天津)股份有限公司 - H股 | | 日期 (日 / 月 / 年): | 01/08/2025 - 01/09/2025 | ...